This study investigates the safety of Radioligand Therapy with [225Ac]Ac-PSMA in patients with metastatic castration-resistant prostate cancer who have progressed after treatment with [177Lu]Lu-PSMA. This evidence concerns the gene FOLH1 and prostate carcinoma.